Skip to main content
View expanded cover

Controversies in Neuro-Ophthalmic Management pp 25–39Cite as

Optic Neuritis

  • 341 Accesses

Abstract

Optic neuritis is an inflammatory optic neuropathy that typically presents with acute to subacute vision loss associated with pain exacerbated by eye movements. While it can be isolated, optic neuritis commonly is associated with an underlying systemic condition, such as multiple sclerosis, neuromyelitis optica spectrum disorder, or myelin oligodendrocyte glycoprotein-associated disorder. Correct diagnosis of these conditions is crucial to permit optimal treatment and accurate prognostication. Clinical presentation and neuroimaging characteristics may help guide clinical suspicion and, thus, further evaluation. Serum and cerebrospinal fluid testing also may contribute to the ultimate diagnosis of the underlying condition.

Keywords

  • Optic neuritis
  • Multiple sclerosis
  • Neuromyelitis optica spectrum disorder
  • Myelin oligodendrocyte glycoprotein
  • Aquaporin-4 antibodies
  • MOG-IgG
  • Magnetic resonance imaging (MRI)

This is a preview of subscription content, access via your institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-3-030-74103-7_4
  • Chapter length: 15 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   129.00
Price excludes VAT (USA)
  • ISBN: 978-3-030-74103-7
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book
USD   119.99
Price excludes VAT (USA)
Hardcover Book
USD   169.99
Price excludes VAT (USA)
Learn about institutional subscriptions
Fig. 4.1
Fig. 4.2
Fig. 4.3
Fig. 4.4
Fig. 4.5
Fig. 4.6
Fig. 4.7
Fig. 4.8

References

  1. Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol. 2008;65(6):727–32.

    Google Scholar 

  2. Taylor BV, Lucas RM, Dear K, Kilpatrick TJ, Pender MP, van der Mei IA, Chapman C, Coulthard A, Dwyer T, McMichael AJ, Valery PC, Williams D, Ponsonby AL. Latitudinal variation in incidence and type of first central nervous system demyelinating events. Mult Scler. 2010;16(4):398–405. https://doi.org/10.1177/1352458509359724.

    CrossRef  PubMed  Google Scholar 

  3. Rodriguez M, Siva A, Cross SA, O’Brien PC, Kurland LT. Optic neuritis: a population-based study in Olmsted County, Minnesota. Neurology. 1995;45(2):244–50.

    CAS  CrossRef  Google Scholar 

  4. Wan MJ, Adebona O, Benson LA, Gorman MP, Heidary G. Visual outcomes in pediatric optic neuritis. Am J Ophthalmol. 2014;158(3):503–7. e502. https://doi.org/10.1016/j.ajo.2014.05.036.

    CrossRef  PubMed  Google Scholar 

  5. Ambika S, Padmalakshmi K, Venkatraman V, Noronha OV. Visual outcomes and clinical manifestations of pediatric optic neuritis in Indian population: an institutional study. J Neuroophthalmol. 2018;38(4):462–5. https://doi.org/10.1097/WNO.0000000000000646.

    CrossRef  PubMed  Google Scholar 

  6. Averseng-Peaureaux D, Mizzi M, Colineaux H, Mahieu L, Pera MC, Brassat D, Chaix Y, Berard E, Deiva K, Cheuret E, Kidbiosep study group. Paediatric optic neuritis: factors leading to unfavourable outcome and relapses. Br J Ophthalmol. 2018;102(6):808–13. https://doi.org/10.1136/bjophthalmol-2016-309978.

    CrossRef  PubMed  Google Scholar 

  7. Waldman AT, Stull LB, Galetta SL, Balcer LJ, Liu GT. Pediatric optic neuritis and risk of multiple sclerosis: meta-analysis of observational studies. J AAPOS. 2011;15(5):441–6. https://doi.org/10.1016/j.jaapos.2011.05.020.

    CrossRef  PubMed  Google Scholar 

  8. Beck RW, Cleary PA, Trobe JD, Kaufman DI, Kupersmith MJ, Paty DW, Brown CH. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. N Engl J Med. 1993;329(24):1764–9.

    CAS  CrossRef  Google Scholar 

  9. Mealy MA, Whetstone A, Orman G, Izbudak I, Calabresi PA, Levy M. Longitudinally extensive optic neuritis as an MRI biomarker distinguishes neuromyelitis optica from multiple sclerosis. J Neurol Sci. 2015;355(1–2):59–63. https://doi.org/10.1016/j.jns.2015.05.013.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  10. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162–73. https://doi.org/10.1016/s1474-4422(17)30470-2.

    CrossRef  PubMed  Google Scholar 

  11. Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, de Seze J, Fujihara K, Greenberg B, Jacob A, Jarius S, Lana-Peixoto M, Levy M, Simon JH, Tenembaum S, Traboulsee AL, Waters P, Wellik KE, Weinshenker BG, International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85(2):177–89.

    CrossRef  Google Scholar 

  12. Jarius S, Wildemann B. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol. 2010;6(7):383–92. https://doi.org/10.1038/nrneurol.2010.72.

    CAS  CrossRef  PubMed  Google Scholar 

  13. Ramanathan S, Prelog K, Barnes EH, Tantsis EM, Reddel SW, Henderson AP, Vucic S, Gorman MP, Benson LA, Alper G, Riney CJ, Barnett M, Parratt JD, Hardy TA, Leventer RJ, Merheb V, Nosadini M, Fung VS, Brilot F, Dale RC. Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. Mult Scler. 2016;22(4):470–82.

    CAS  CrossRef  Google Scholar 

  14. Song H, Zhou H, Yang M, Wang J, Liu H, Sun M, Xu Q, Wei S. Different characteristics of aquaporin-4 and myelin oligodendrocyte glycoprotein antibody-seropositive male optic neuritis in China. J Ophthalmol. 2019;2019:4015075. https://doi.org/10.1155/2019/4015075.

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  15. Akaishi T, Sato DK, Takahashi T, Nakashima I. Clinical spectrum of inflammatory central nervous system demyelinating disorders associated with antibodies against myelin oligodendrocyte glycoprotein. Neurochem Int. 2019;130:104319. https://doi.org/10.1016/j.neuint.2018.10.016.

    CAS  CrossRef  PubMed  Google Scholar 

  16. Scott TF, Kassab SL, Pittock SJ. Neuromyelitis optica IgG status in acute partial transverse myelitis. Arch Neurol. 2006;63(10):1398–400.

    CrossRef  Google Scholar 

  17. Hassan MB, Stern C, Flanagan EP, Pittock SJ, Kunchok A, Foster RC, Jitprapaikulsan J, Hodge DO, Bhatti MT, Chen JJ. Population based incidence of optic neuritis in the era of aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies. Am J Ophthalmol. 2020;220:110–4. https://doi.org/10.1016/j.ajo.2020.07.014.

    CAS  CrossRef  PubMed  Google Scholar 

  18. Kang H, Chen T, Li H, Xu Q, Cao S, Wei S. Prognostic factors and disease course in aquaporin-4 antibody-positive Chinese patients with acute optic neuritis. J Neurol. 2017;264(10):2130–40. https://doi.org/10.1007/s00415-017-8606-9.

    CAS  CrossRef  PubMed  Google Scholar 

  19. Chen JJ, Flanagan EP, Jitprapaikulsan J, Lopez-Chiriboga ASS, Fryer JP, Leavitt JA, Weinshenker BG, McKeon A, Tillema JM, Lennon VA, Tobin WO, Keegan BM, Lucchinetti CF, Kantarci OH, McClelland CM, Lee MS, Bennett JL, Pelak VS, Chen Y, VanStavern G, Adesina OO, Eggenberger ER, Acierno MD, Wingerchuk DM, Brazis PW, Sagen J, Pittock SJ. Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome. Am J Ophthalmol. 2018;195:8–15. https://doi.org/10.1016/j.ajo.2018.07.020.

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  20. Liu H, Zhou H, Wang J, Xu Q, Wei S. Antibodies to myelin oligodendrocyte glycoprotein in chronic relapsing inflammatory optic neuropathy. Br J Ophthalmol. 2019;103(10):1423–8. https://doi.org/10.1136/bjophthalmol-2018-313142.

    CrossRef  PubMed  Google Scholar 

  21. Jitprapaikulsan J, Chen JJ, Flanagan EP, Tobin WO, Fryer JP, Weinshenker BG, McKeon A, Lennon VA, Leavitt JA, Tillema JM, Lucchinetti C, Keegan BM, Kantarci O, Khanna C, Jenkins SM, Spears GM, Sagan J, Pittock SJ. Aquaporin-4 and myelin oligodendrocyte glycoprotein autoantibody status predict outcome of recurrent optic neuritis. Ophthalmology. 2018;125(10):1628–37. https://doi.org/10.1016/j.ophtha.2018.03.041.

    CrossRef  PubMed  Google Scholar 

  22. Chen JJ, Tobin WO, Majed M, Jitprapaikulsan J, Fryer JP, Leavitt JA, Flanagan EP, McKeon A, Pittock SJ. Prevalence of myelin oligodendrocyte glycoprotein and aquaporin-4-IgG in patients in the optic neuritis treatment trial. JAMA Ophthalmol. 2018;136(4):419–22. https://doi.org/10.1001/jamaophthalmol.2017.6757.

  23. Zhao Y, Tan S, Chan TCY, Xu Q, Zhao J, Teng D, Fu H, Wei S. Clinical features of demyelinating optic neuritis with seropositive myelin oligodendrocyte glycoprotein antibody in Chinese patients. Br J Ophthalmol. 2018;102(10):1372–7. https://doi.org/10.1136/bjophthalmol-2017-311177.

    CrossRef  PubMed  Google Scholar 

  24. Akaishi T, Sato DK, Nakashima I, Takeshita T, Takahashi T, Doi H, Kurosawa K, Kaneko K, Kuroda H, Nishiyama S, Misu T, Nakazawa T, Fujihara K, Aoki M. MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study. J Neurol Neurosurg Psychiatry. 2016;87(4):446–8.

    CrossRef  Google Scholar 

  25. Peng Y, Liu L, Zheng Y, Qiao Z, Feng K, Wang J. Diagnostic implications of MOG/AQP4 antibodies in recurrent optic neuritis. Exp Ther Med. 2018;16(2):950–8. https://doi.org/10.3892/etm.2018.6273.

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  26. Lopez-Chiriboga AS, Van Stavern G, Flanagan EP, Pittock SJ, Fryer J, Bhatti MT, Chen JJ. Myelin oligodendrocyte glycoprotein antibody (MOG-IgG)-positive optic perineuritis. Neuro-Ophthalmology. 2019;44(1):1–4. https://doi.org/10.1080/01658107.2019.1607883.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  27. Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, Pache F, Stich O, Beume LA, Hummert MW, Ringelstein M, Trebst C, Winkelmann A, Schwarz A, Buttmann M, Zimmermann H, Kuchling J, Franciotta D, Capobianco M, Siebert E, Lukas C, Korporal-Kuhnke M, Haas J, Fechner K, Brandt AU, Schanda K, Aktas O, Paul F, Reindl M, Wildemann B, cooperation with the Neuromyelitis Optica Study Group (NEMOS). MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation. 2016;13(1):280. https://doi.org/10.1186/s12974-016-0718-0.

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  28. Salama S, Pardo S, Levy M. Clinical characteristics of myelin oligodendrocyte glycoprotein antibody neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2019;30:231–5. https://doi.org/10.1016/j.msard.2019.02.023.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  29. Ishikawa H, Kezuka T, Shikishima K, Yamagami A, Hiraoka M, Chuman H, Nakamura M, Hoshi K, Goseki T, Mashimo K, Mimura O, Yoshitomi T, Tanaka K, Working Group on Diagnostic Criteria for Refractory Optic Neuritis Based on Neuroimmunological Perspective. Epidemiologic and clinical characteristics of optic neuritis in Japan. Ophthalmology. 2019;126(10):1385–98. https://doi.org/10.1016/j.ophtha.2019.04.042.

    CrossRef  PubMed  Google Scholar 

  30. Fernandes DB, Ramos Rde I, Falcochio C, Apostolos-Pereira S, Callegaro D, Monteiro ML. Comparison of visual acuity and automated perimetry findings in patients with neuromyelitis optica or multiple sclerosis after single or multiple attacks of optic neuritis. J Neuroophthalmol. 2012;32(2):102–6. https://doi.org/10.1097/WNO.0b013e31823a9ebc.

    CrossRef  PubMed  Google Scholar 

  31. Matiello M, Lennon VA, Jacob A, Pittock SJ, Lucchinetti CF, Wingerchuk DM, Weinshenker BG. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology. 2008;70(23):2197–200.

    CAS  CrossRef  Google Scholar 

  32. Martinez-Hernandez E, Sepulveda M, Rostasy K, Hoftberger R, Graus F, Harvey RJ, Saiz A, Dalmau J. Antibodies to aquaporin 4, myelin-oligodendrocyte glycoprotein, and the glycine receptor alpha1 subunit in patients with isolated optic neuritis. JAMA Neurol. 2015;72(2):187–93. https://doi.org/10.1001/jamaneurol.2014.3602.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  33. Sotirchos ES, Filippatou A, Fitzgerald KC, Salama S, Pardo S, Wang J, Ogbuokiri E, Cowley NJ, Pellegrini N, Murphy OC, Mealy MA, Prince JL, Levy M, Calabresi PA, Saidha S. Aquaporin-4 IgG seropositivity is associated with worse visual outcomes after optic neuritis than MOG-IgG seropositivity and multiple sclerosis, independent of macular ganglion cell layer thinning. Mult Scler. 2019;26(11):1360–71.

    CrossRef  Google Scholar 

  34. Pache F, Zimmermann H, Mikolajczak J, Schumacher S, Lacheta A, Oertel FC, Bellmann-Strobl J, Jarius S, Wildemann B, Reindl M, Waldman A, Soelberg K, Asgari N, Ringelstein M, Aktas O, Gross N, Buttmann M, Ach T, Ruprecht K, Paul F, Brandt AU. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. J Neuroinflammation. 2016;13(1):282. https://doi.org/10.1186/s12974-016-0720-6.

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  35. Beck RW, Cleary PA, Anderson MMJ, Keltner JL, Shults WT, Kaufman DI, Buckley EG, Corbett JJ, Kupersmith MJ, Miller NR, Savino PJ, Guy JR, Trobe JD, McCrary JAI, Smith CH, Chrousos GA, Thompson HS, Katz BJ, Brodsky MC, Goodwin JA, Atwell CW, Group TONS. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med. 1992;326(9):581–8.

    CAS  CrossRef  Google Scholar 

  36. Morrow SA, Fraser JA, Day C, Bowman D, Rosehart H, Kremenchutzky M, Nicolle M. Effect of treating acute optic neuritis with bioequivalent Oral vs intravenous corticosteroids: a randomized clinical trial. JAMA Neurol. 2018;75(6):690–6. https://doi.org/10.1001/jamaneurol.2018.0024.

    CrossRef  PubMed  PubMed Central  Google Scholar 

  37. Le Page E, Veillard D, Laplaud DA, Hamonic S, Wardi R, Lebrun C, Zagnoli F, Wiertlewski S, Deburghgraeve V, Coustans M, Edan G, Neuroscience CiWNfEi. Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial. Lancet. 2015;386(9997):974–81.

    CrossRef  Google Scholar 

  38. Trebst C, Jarius S, Berthele A, Paul F, Schippling S, Wildemann B, Borisow N, Kleiter I, Aktas O, Kumpfel T, Neuromyelitis Optica Study Group (NEMOS). Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol. 2014;261(1):1–16. https://doi.org/10.1007/s00415-013-7169-7.

    CAS  CrossRef  PubMed  Google Scholar 

  39. Bonnan M, Valentino R, Debeugny S, Merle H, Fergé J-L, Mehdaoui H, Cabre P. Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry. 2018;89(4):346–51. https://doi.org/10.1136/jnnp-2017-316286.

    CrossRef  PubMed  Google Scholar 

  40. Burton JM, Freedman MS. The shifting landscape of disease-modifying therapies for relapsing multiple sclerosis. J Neuroophthalmol. 2018;38(2):210–6. https://doi.org/10.1097/WNO.0000000000000659.

    CrossRef  PubMed  Google Scholar 

  41. Barnett MH, Prineas JW, Buckland ME, Parratt JD, Pollard JD. Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy. Mult Scler. 2012;18(1):108–12. https://doi.org/10.1177/1352458511421185.

    CAS  CrossRef  PubMed  Google Scholar 

  42. Min J-H, Kim BJ, Lee KH. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler J. 2011;18(1):113–5. https://doi.org/10.1177/1352458511431973.

    CAS  CrossRef  Google Scholar 

  43. Palace J, Leite MI, Nairne A, Vincent A. Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol. 2010;67:1016–7. https://doi.org/10.1136/jnnp.2009.

    CrossRef  PubMed  Google Scholar 

  44. Papeix C, Vidal JS, de Seze J, Pierrot-Deseilligny C, Tourbah A, Stankoff B, Lebrun C, Moreau T, Vermersch P, Fontaine B, Lyon-Caen O, Gout O. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler. 2007;13(2):256–9.

    CAS  CrossRef  Google Scholar 

  45. Tanaka M, Tanaka K, Komori M. Interferon-beta(1b) treatment in neuromyelitis optica. Eur Neurol. 2009;62(3):167–70. https://doi.org/10.1159/000227277.

    CAS  CrossRef  PubMed  Google Scholar 

  46. Cabre P, Mejdoubi M, Jeannin S, Merle H, Plumelle Y, Cavillon G, Smadja D, Marignier R, Francophone Society of Multiple Sclerosis and OFSEP investigators. Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study. J Neurol. 2018;265(4):917–25. https://doi.org/10.1007/s00415-018-8771-5.

    CAS  CrossRef  PubMed  Google Scholar 

  47. Shaygannejad V, Fayyazi E, Badihian S, Mirmosayyeb O, Manouchehri N, Ashtari F, Asgari N. Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective study. J Neurol. 2019;266(3):642–50. https://doi.org/10.1007/s00415-019-09180-9.

    CAS  CrossRef  PubMed  Google Scholar 

  48. Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, Nakashima I, Terzi M, Totolyan N, Viswanathan S, Wang KC, Pace A, Fujita KP, Armstrong R, Wingerchuk DM. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(7):614–25. https://doi.org/10.1056/NEJMoa1900866.

    CAS  CrossRef  PubMed  Google Scholar 

  49. Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung H-P, Lublin FD, Drappa J, Barron G, Madani S, Ratchford JN, She D, Cimbora D, Katz E. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet. 2019;394(10206):1352–63. https://doi.org/10.1016/s0140-6736(19)31817-3.

    CAS  CrossRef  PubMed  Google Scholar 

  50. Traboulsee A, Greenberg BM, Bennett JL, Szczechowski L, Fox E, Shkrobot S, Yamamura T, Terada Y, Kawata Y, Wright P, Gianella-Borradori A, Garren H, Weinshenker BG. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 2020;19(5):402–12. https://doi.org/10.1016/s1474-4422(20)30078-8.

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  51. Oliveira LM, Apóstolos-Pereira SL, Pitombeira MS, Bruel Torretta PH, Callegaro D, Sato DK. Persistent MOG-IgG positivity is a predictor of recurrence in MOG-IgG-associated optic neuritis, encephalitis and myelitis. Mult Scler. 2019;25(14):1907–14.

    CAS  CrossRef  Google Scholar 

  52. Chen JJ, Bhatti MT. Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis. Curr Opin Neurol. 2019;33(1):47–54. https://doi.org/10.1097/WCO.0000000000000766.

    CAS  CrossRef  Google Scholar 

  53. Novi G, Gastaldi M, Franciotta D, Pesce G, Benedetti L, Uccelli A. Tocilizumab in MOG-antibody spectrum disorder: a case report. Mult Scler Relat Disord. 2019;27:312–4. https://doi.org/10.1016/j.msard.2018.11.012.

    CAS  CrossRef  PubMed  Google Scholar 

  54. Chen JJ, Flanagan EP, Bhatti MT, Jitprapaikulsan J, Dubey D, Lopez Chiriboga ASS, Fryer JP, Weinshenker BG, McKeon A, Tillema JM, Lennon VA, Lucchinetti CF, Kunchok A, McClelland CM, Lee MS, Bennett JL, Pelak VS, Van Stavern G, Adesina OO, Eggenberger ER, Acierno MD, Wingerchuk DM, Lam BL, Moss H, Beres S, Gilbert AL, Shah V, Armstrong G, Heidary G, Cestari DM, Stiebel-Kalish H, Pittock SJ. Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Neurology. 2020;95(2):e111–20. https://doi.org/10.1212/WNL.0000000000009758.

    CAS  CrossRef  PubMed  Google Scholar 

  55. Seay M, Rucker JC. Neuromyelitis Optica: review and utility of testing aquaporin-4 antibody in typical optic neuritis. Asia Pac J Ophthalmol. 2018;7(4):229–34. https://doi.org/10.22608/APO.2018170.

    CAS  CrossRef  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Neuro-Ophthalmology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Amanda D. Henderson

Authors
  1. Amanda D. Henderson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amanda D. Henderson .

Editor information

Editors and Affiliations

  1. Division of Neuro-Ophthalmology Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    MD Amanda D. Henderson

  2. Division of Neuro-Ophthalmology Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    MD Andrew R. Carey

Rights and permissions

Reprints and Permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Verify currency and authenticity via CrossMark

Cite this chapter

Henderson, A.D. (2021). Optic Neuritis. In: Henderson, A.D., Carey, A.R. (eds) Controversies in Neuro-Ophthalmic Management. Springer, Cham. https://doi.org/10.1007/978-3-030-74103-7_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-74103-7_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-74102-0

  • Online ISBN: 978-3-030-74103-7

  • eBook Packages: MedicineMedicine (R0)